Literature DB >> 11734579

Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins.

J W Gaubatz1, R C Hoogeveen, A S Hoffman, K G Ghazzaly, H J Pownall, J Guevara, M L Koschinsky, J D Morrisett.   

Abstract

Lipoprotein [a] (Lp[a]) is a cholesterol-rich lipoprotein resembling LDL to which a large polymorphic glycoprotein, apolipoprotein [a] (apo[a]), is covalently coupled. Lp[a] usually exists as a free-standing particle in normolipidemic subjects; however, it can associate noncovalently with triglyceride-rich lipoproteins in hypertriglyceridemic (HTG) subjects. In this study, 10-78% of the Lp[a] present in five HTG subjects was found in the triglyceride-rich lipoprotein (TRL) fraction. The Lp[a]-TRL complex was resistant to dissociation by ultracentrifugation (UCF) alone, but was quantitatively dissociated by UCF in the presence of 100 mM proline. Of this dissociated Lp[a], 70-88% was in the form of a lipoprotein resembling conventional Lp[a]. Incubation of Lp[a]-depleted TRL with native Lp[a] resulted in a reconstituted Lp[a]-TRL complex that closely resembled the native isolates in all examined properties. Complex formation was inhibited by several compounds in the order proline > tranexamate > epsilon-aminocaproate >> arginine > lysine. Neither plasminogen nor LDL inhibited binding of Lp[a] to TRL. We observed the preferential binding of Lp[a] containing higher apparent molecular weight apo[a] polymorphs to TRL both in native and reconstituted Lp[a]-TRL complexes. A disproportionate amount of Lp[a] was bound to the larger TRL particles. Although most apo[a] bound to TRL was in the form of conventional Lp[a] particles, lipid-free recombinant apo[a] was observed to bind TRL. These results provide unequivocal evidence of the existence of an Lp[a]-TRL complex under pathophysiologic conditions. The metabolic fate of the Lp[a]-TRL complex, which is more abundant in hypertriglyceridemia, may be different from that of conventional Lp[a], and may contribute uniquely to the progression or severity of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734579

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  10 in total

1.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

Review 2.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

3.  Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Authors:  Justin R Clark; Matthew Gemin; Amer Youssef; Santica M Marcovina; Annik Prat; Nabil G Seidah; Robert A Hegele; Michael B Boffa; Marlys L Koschinsky
Journal:  J Lipid Res       Date:  2022-04-22       Impact factor: 6.676

4.  Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Authors:  Margaret R Diffenderfer; Stefania Lamon-Fava; Santica M Marcovina; P Hugh R Barrett; Julian Lel; Gregory G Dolnikowski; Lars Berglund; Ernst J Schaefer
Journal:  Metabolism       Date:  2015-11-06       Impact factor: 8.694

5.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

6.  Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Authors:  Renu Nandakumar; Anastasiya Matveyenko; Tiffany Thomas; Marianna Pavlyha; Colleen Ngai; Stephen Holleran; Rajasekhar Ramakrishnan; Henry N Ginsberg; Wahida Karmally; Santica M Marcovina; Gissette Reyes-Soffer
Journal:  J Lipid Res       Date:  2018-10-07       Impact factor: 5.922

Review 7.  LDL-apheresis: technical and clinical aspects.

Authors:  Rolf Bambauer; Carolin Bambauer; Boris Lehmann; Reinhard Latza; Ralf Schiel
Journal:  ScientificWorldJournal       Date:  2012-04-30

8.  Application of protein lysate microarrays to molecular marker verification and quantification.

Authors:  Anitha Ramaswamy; E Lin; Iou Chen; Rahul Mitra; Joel Morrisett; Kevin Coombes; Zhenlin Ju; Mini Kapoor
Journal:  Proteome Sci       Date:  2005-11-10       Impact factor: 2.480

9.  Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).

Authors:  Xiang Zhang; Lotte C A Stiekema; Erik S G Stroes; Albert K Groen
Journal:  Lipids Health Dis       Date:  2020-05-11       Impact factor: 3.876

Review 10.  Lp(a): When and how to measure it.

Authors:  Jaimini Cegla; Michael France; Santica M Marcovina; R Dermot G Neely
Journal:  Ann Clin Biochem       Date:  2020-10-28       Impact factor: 2.057

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.